Advertisement

Search Results

Advertisement



Your search for Julia Cipriano, MD matches 31 pages

Showing 1 - 31


lung cancer

AI and the Future of Lung Cancer Screening: Still Room for Improvement

  “Artificial intelligence [AI] will be used in all aspects of [lung cancer] screening…, and it continues to get better,” commented topic overview speaker David F. Yankelevitz, MD, Professor of Radiology at the Icahn School of Medicine at Mount Sinai, New York, at the Quantitative Imaging...

lung cancer

CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

The multicenter phase III -CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...

gynecologic cancers

Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer

Based on results from the ongoing multicenter phase III CHIPOR trial, which were reported in The Lancet Oncology Jean-Marc Classe, MD, PhD, Head of the Oncological Surgery Department at the Institut de Cancérologie de l’Ouest, Saint Herblain, France, and colleagues, the addition of hyperthermic...

lymphoma

Determining the Optimal First-Line Management of Advanced Classical Hodgkin Lymphoma

“While clinical trials emphasize improvement in cure rates for patients with advanced classical Hodgkin lymphoma, an important goal is reducing the potential long-term effects of treatment,” commented Iris Isufi, MD, of the Smilow Cancer Hospital and Yale Cancer Center, New Haven, Connecticut, and ...

lung cancer

4-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

Neoadjuvant chemotherapy with vs without the PD-1 inhibitor nivolumab conferred a higher pathologic complete response rate and long-term event-free survival benefit in Asian patients with resectable non–small cell lung cancer (NSCLC), according to the global phase III CheckMate 816 trial. At the...

supportive care
issues in oncology

Exploring Issues in Oncofertility

  “Cancer in young adults is more complicated in part [because of the risk of] infertility and premature menopause,” commented Ann H. Partridge, MD, MPH, FASCO, Interim Chair, Department of Medical Oncology; the Eric P. Winer, MD Chair in Breast Cancer Research, Dana-Farber Cancer Institute; and ...

lung cancer

TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC

The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...

lung cancer

CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...

lung cancer

TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC

The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...

lung cancer

CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...

breast cancer

EMBER: Imlunestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer

In the the phase IA/B dose-escalation and -expansion EMBER study reported in the Journal of Clinical Oncology by Jhaveri et al, the next-generation oral selective estrogen receptor degrader imlunestrant (alone and in combination with other targeted therapies) demonstrated a manageable safety...

lung cancer

AEGEAN Update Confirms Benefit of Perioperative Durvalumab in Resectable NSCLC

The second planned interim analysis of the global phase III AEGEAN trial—reported by John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer...

bladder cancer

NURE-Combo: First Results for a Perioperative Chemoimmunotherapy Approach in Muscle-Invasive Bladder Cancer

Based on the first results of the single-center phase II NURE-Combo trial, which were reported in the Journal of Clinical Oncology (JCO) by Mercinelli et al, the combination of neoadjuvant nivolumab plus nab-paclitaxel followed by postsurgical adjuvant nivolumab appeared to be safe and active in...

lung cancer

Taletrectinib in ROS1-Positive NSCLC: Focus on Prior Tyrosine Kinase Inhibitor Exposure Status

Updated data from the global, multicenter, single-arm phase II TRUST-II trial, which were reported by Liu et al during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract MA06.03), continued to demonstrate robust overall and...

Addition of Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy for Early Breast Cancer

In a meta-analysis reported in JAMA Oncology, Villacampa et al found that the addition of neoadjuvant immune checkpoint inhibitor treatment to chemotherapy was associated with improved outcomes among subgroups of patients with early breast cancer.   Study Details A literature search through...

breast cancer

Impact of Breast Cancer Screening Interval on Stage at Diagnosis and Overall Survival

Annual mammographic screening appeared to be associated with a reduced risk of late-stage breast cancer and an overall survival benefit across clinical and demographic subgroups of patients older than age 40, according to an observational analysis reported by Zuley et al in the Journal of Clinical...

skin cancer
immunotherapy

Remembering a Pioneer in Melanoma and Immunotherapy: Jeffrey S. Weber, MD, PhD, FASCO

Jeffrey S. Weber, MD, PhD, FASCO, an internationally recognized pioneer in melanoma and cancer immunotherapy, died on August 19, 2024, according to an announcement from the Melanoma Research Foundation. He most recently served as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at...

breast cancer

Breast Cancer Index Confirmed as Prognostic in a SOFT Trial–Derived Population

A prospective-retrospective translational study reported in JAMA Oncology by Ruth M. O’Regan, MD, and colleagues confirmed the prognostic value of the Breast Cancer Index (BCI) in a Suppression of Ovarian Function Trial (SOFT) trial–derived population of premenopausal women with early-stage,...

issues in oncology
supportive care

Risk of Suicidal Behavior Among Spouses of Patients With Cancer

The risk of suicidal behavior may be increased among the spouses of patients with cancer, according to a retrospective Danish population-based cohort study reported by Liu et al in JAMA Oncology. Clinical and societal awareness was thus deemed essential, particularly during the first year after...

skin cancer

Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.1...

breast cancer

Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality?

The results of a contemporary U.S. population–based cohort study published by Giannakeas et al in JAMA Oncology revealed that patients with unilateral breast cancer had an increased risk of breast cancer–related death after developing contralateral disease. Although the findings also showed a...

prostate cancer
cardio-oncology

Patients With Prostate Cancer: Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes

Based on the results of a retrospective cohort study published by Demissei et al in JACC: CardioOncology, Black patients with prostate cancer who received systemic androgen-deprivation therapy (ADT) seemed to have a significantly greater likelihood of experiencing adverse cardiovascular disease...

cardio-oncology

Does Neighborhood Walkability Impact the Burden of Cardiovascular Risk Factors in Patients With Cancer?

The results of a cross-sectional study reported in JACC: CardioOncology by Nwana et al revealed a significant association between the extent to which a neighborhood facilitates walking and the burden of modifiable cardiovascular risk factors among patients with a history of cancer. “[The findings...

immunotherapy

Immunotherapy-Induced Multiorgan Immune-Related Adverse Events: Co-occurrence Patterns and Prognostic Implications

The results of a retrospective multicohort study, reported in The Lancet Oncology by Wan et al, suggested that the identification of the immune-related adverse event cluster to which a patient belongs may aid in prognosticating response to immunotherapy. “These insights can be leveraged to counsel...

issues in oncology

Can GLP-1 Receptor Agonists Prevent Obesity-Associated Cancers in Patients With Type 2 Diabetes?

Based on the results of a retrospective U.S. population–based cohort study, which were reported in JAMA Network Open by Wang et al, treatment with glucagon-like peptide 1 (GLP-1) receptor agonists vs insulins seemed to be associated with a decreased risk of developing specific obesity-associated...

head and neck cancer

Nasopharyngeal Carcinoma: Adding Sintilimab to Standard Chemoradiotherapy for Locoregionally Advanced Disease

Based on the results of the Chinese multicenter phase III CONTINUUM trial, which were reported in The Lancet by Liu et al, the addition of the PD-1 inhibitor sintilimab to standard chemoradiotherapy seemed to improve event-free survival—albeit with more frequent but manageable adverse events—in...

hepatobiliary cancer

Nonplatinum Chemotherapy Regimen for Advanced Cholangiocarcinoma

Based on the results of the multicenter phase II NIFE-AIO-YMO HEP-0315 trial, which were reported in the Journal of Clinical Oncology by Ettrich et al, first-line palliative treatment with nanoliposomal irinotecan plus fluorouracil and leucovorin appears to be safe and active in patients with...

colorectal cancer

Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP

As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...

skin cancer

Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma

As reported at the 2024 ASCO Annual Meeting (Abstract 9500) and in The New England Journal of Medicine by Georgina V. Long, MD, PhD, and colleagues, the final, 8-year follow-up analysis of the phase III COMBI-AD trial has shown continued improvements in relapse-free and distant metastasis–free...

gastrointestinal cancer
neuroendocrine tumors

Advanced Neuroendocrine Tumors: Adding Lu-177 Dotatate to Standard First-Line Therapy

As reported in The Lancet by Simron Singh, MD, MPH, FRCPC, and colleagues, primary results of the international, multicenter, randomized phase III NETTER-2 study have shown significantly improved progression-free survival with the addition of the radioligand lutetium-177 dotatate (Lu-177 dotatate)...

multiple myeloma
breast cancer
bladder cancer
gynecologic cancers
skin cancer
pancreatic cancer

NCCN Clinical Practice Guidelines in Oncology: 2024 Updates

The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...

Advertisement

Advertisement




Advertisement